Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
View Patent ↗A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.
1. A method for treating cervical dystonia, the method comprising the step of administering to a human patient a therapeutically effective amount of a neurotoxic component of a Botulinum toxin type B to thereby treat the patient's cervical dystonia, wherein the neurotoxic component administered to the patient has a molecular weight of about 150 kilodaltons.
2. The method of claim 1 , wherein between about 100 units and about 1000 units of the neurotoxic component is administered.
3. The method of claim 1 , wherein alleviation of the cervical dystonia occurs in about 3 to about 7 days.
4. A method for treating cervical dystonia, the method comprising the step of administering to a human patient a therapeutically effective amount of a neurotoxic component from a single Botulinum toxin type to thereby treat the patient's cervical dystonia, wherein the neurotoxic component administered to the patient has a molecular weight of about 150 kilodaltons, and wherein said Botulinum toxin is Botulinum toxin type B.
5. A method for treating cervical dystonia, the method comprising the step of administering to a human patient a therapeutically effective amount of a neurotoxic component from only a Botulinum toxin type B to thereby treat the patient's cervical dystonia, wherein the neurotoxic component administered to the patient has a molecular weight of about 150 kilodaltons.
6. The method of claim 1 , wherein between about 80 units and about 460 units of the neurotoxic component is administered.
7. The method of claim 1 , wherein the neurotoxic component is administered by intramuscular injection.
8. The method of claim 1 , wherein an alleviation of a symptom of the cervical dystonia is evident 3 to 7 days after the administration of the neurotoxic component.
9. The method of claim 4 , wherein between about 100 units and about 1000 units of the neurotoxic component is administered.
10. The method of claim 4 , wherein between about 80 units and about 460 units of the neurotoxic component is administered.
11. The method of claim 4 , wherein the neurotoxic component is administered by intramuscular injection.
12. The method of claim 4 , wherein alleviation of the cervical dystonia occurs in about 3 to about 7 days.
13. The method of claim 4 , wherein an alleviation of a symptom of the cervical dystonia is evident 3 to 7 days after the administration of the neurotoxic component.
14. The method of claim 5 , wherein between about 100 units and about 1000 units of the neurotoxic component is administered.
15. The method of claim 5 , wherein between about 80 units and about 460 units of the neurotoxic component is administered.
16. The method of claim 5 , wherein the neurotoxic component is administered by intramuscular injection.
17. The method of claim 5 , wherein alleviation of the cervical dystonia occurs in about 3 to about 7 days.
18. The method of claim 5 , wherein an alleviation of a symptom of the cervical dystonia is evident 3 to 7 days after the administration of the neurotoxic component.
19. A method for treating cervical dystonia, the method comprising the step of administering to a human patient an effective amount of a neurotoxic component of a Botulinum toxin type B, thereby reducing the severity of an abnormal head position symptom of cervical dystonia, wherein the neurotoxic component administered to the patient has a molecular weight of about 150 kilodaltons.
20. The method of claim 19 , wherein between about 100 units and about 1000 units of the neurotoxic component is administered.
21. The method of claim 19 , wherein between about 80 units and about 460 units of the neurotoxic component is administered.
22. The method of claim 19 , wherein the neurotoxic component is administered by intramuscular injection.
23. The method of claim 19 , wherein said severity is reduced in about 3 to about 7 days.
24. The method of claim 19 , wherein reduction in said severity is evident 3 to 7 days after the administration of the neurotoxic component.
25. A method for treating cervical dystonia, the method comprising the step of administering to a human patient an effective amount of a neurotoxic component of a Botulinum toxin type B, thereby reducing a neck pain symptom of cervical dystonia, wherein the neurotoxic component administered to the patient has a molecular weight of about 150 kilodaltons.
26. The method of claim 25 , wherein between about 100 units and about 1000 units of the neurotoxic component is administered.
27. The method of claim 25 , wherein between about 80 units and about 460 units of the neurotoxic component is administered.
28. The method of claim 25 , wherein the neurotoxic component is administered by intramuscular injection.
29. The method of claim 25 , wherein said symptom is reduced in about 3 to about 7 days.
30. The method of claim 25 , wherein reduction in said symptom is evident 3 to 7 days after the administration of the neurotoxic component.